Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma

BACKGROUND: Programmed death receptor-1 (PD-1) inhibitors have been approved as second-line treatment regimen in hepatocellular carcinoma (HCC), but it is still worth studying whether patients can benefit from PD-1 inhibitors as first-line drugs combined with targeted drugs and locoregional therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yan-Yu, Yang, Xu, Wang, Yun-Chao, Long, Jun-Yu, Sun, Hui-Shan, Li, Yi-Ran, Xun, Zi-Yu, Zhang, Nan, Xue, Jing-Nan, Ning, Cong, Zhang, Jun-Wei, Zhu, Cheng-Pei, Zhang, Long-Hao, Yang, Xiao-Bo, Zhao, Hai-Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037246/
https://www.ncbi.nlm.nih.gov/pubmed/36970591
http://dx.doi.org/10.3748/wjg.v29.i10.1614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037246/
https://www.ncbi.nlm.nih.gov/pubmed/36970591
http://dx.doi.org/10.3748/wjg.v29.i10.1614

Ejemplares similares